Stryker has achieved an 11.2% increase in revenue in 2025, fuelled by high growth in the company’s vascular business.
The medtech giant achieved FY25 revenues of $25.1bn, representing an 11.2% rise on FY24 at $22.59bn. Releasing its financial results after market close on 29 January, Stryker’s shares on the New York Stock Exchange (NYSE) were up by 2.46% at $363 per share ahead of market open on 30 January, versus a previous close of $354.30. Stryker has a market cap of $135.49bn.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Stryker’s medsurg and neurotechnology portfolio swelled by 15.7% to $15.64bn in 2025, up from $13.51 in FY24. The portfolio’s medical, endoscopy, and instruments lines drew in the most revenue at $4.2bn, $3.8bn, and $3.18bn, with respective rises on FY24 of 9.1% and 12.3% apiece for endoscopy and instruments. Meanwhile, medical rose by 9.1% to $4.2bn, and neuro cranial by 16.3% to $2.48bn.
Stryker’s vascular business, however, saw the biggest growth, with FY25 revenues of $1.97bn corresponding to a 50.6% rise on this line’s performance at $1.3bn in FY24.
Stryker concluded the $4.9bn acquisition of Inari Medical in February 2025, with the company now known as Stryker’s peripheral vascular business, tucking in to its broader vascular line.
In a conference call, Jason Beach, Stryker’s vice president of finance & investor relations, noted that Inari had a strong finish to the year that was highlighted by “robust procedural growth in the high teens”.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataMeanwhile, Stryker’s orthopaedics portfolio achieved FY25 revenues of $9.46bn, denoting a 4.3% rise on FY24. Trauma and extremities was the strongest performing line, with growth of 12.6% to $3.94bn versus $3.50bn in FY24. This was followed by knees and hips, with rises of 8.5% and 9.5% to $2.65bn and $1.86bn, respectively.
Beach attributed the strong performance in knees and hips to Stryker’s Mako 4 robotic system for total knee and hip procedures, stating that Stryker delivered a “stunning” Q4 in relation to Mako installations, with an installed base now totalling over 3,000 worldwide.
“Alongside our record number of installations, we also continue to see steady increases in utilisation bolstering our number one position in US knees and hips,” Beach said. “As we exited the year, over two thirds of our knees and over one third of our hips were performed on Mako in the US.”
Looking ahead to 2026, Stryker expects earnings to fall in the $14.90 to $15.10 range.
Alongside Stryker’s FY25 results, the company also released its Q4 2025 financials. Revenues for the quarter totalled $7.17bn, reflecting an 11.4% on Q4 2024. According to London Stock Exchange Group (LSEG) data seen by Reuters, the total for the quarter exceeded analysts’ expectation of $7.12bn.
Commenting on FY25, Stryker CEO Kevin A. Lobo said: “Having surpassed $25 billion in revenue, we enter 2026 with significant momentum and are poised to continue delivering growth at the high end of medtech.”
